The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LGND | +59.01% | +274.69% | +30.24% | +579% |
| S&P | +12.94% | +86.25% | +13.25% | +1,410% |
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $115.46M | 122.8% |
| Gross Profit | $103.56M | 151.9% |
| Gross Margin | 89.70% | 10.4% |
| Market Cap | $3.47B | 89.8% |
| Market Cap / Employee | $51.05M | 0.0% |
| Employees | 68 | 17.2% |
| Net Income | $117.27M | 1735.2% |
| EBITDA | $62.85M | 206.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $139.38M | 119.1% |
| Accounts Receivable | $57.56M | 67.7% |
| Inventory | 11.9 | -39.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $449.91M | 7079.0% |
| Short Term Debt | $1.09M | -0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.00% | -1.3% |
| Return On Invested Capital | 2.54% | -9.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $13.15M | -63.2% |
| Operating Free Cash Flow | $13.16M | -63.8% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 13.74 | 36.45 | 39.82 | 85.26 | 246.31% |
| Price to Book | 2.39 | 2.42 | 2.75 | 4.15 | 77.55% |
| Price to Sales | 12.16 | 11.12 | 12.08 | 14.55 | 20.26% |
| Price to Tangible Book Value | 7.68 | 7.34 | 8.86 | 12.14 | 105.18% |
| Price to Free Cash Flow TTM | 21.45 | 39.97 | 42.56 | 119.26 | 377.77% |
| Enterprise Value to EBITDA | 163.60 | -66.38 | 108.60 | 54.75 | -31.12% |
| Free Cash Flow Yield | 4.7% | 2.5% | 2.3% | 0.8% | -79.07% |
| Return on Equity | -0.5% | -16.6% | -9.5% | 5.4% | -9.54% |
| Total Debt | $7.11M | $4.45M | $5.74M | $451.00M | 6030.18% |
No podcast episodes available.
LGND earnings call for the period ending September 30, 2021.
LGND earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
